Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise.
From other sites
at CNBC.com (Feb 24, 2012)
at CNBC.com (Jun 24, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs